Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study

Frederik B. Thomsen MD, PhD1,2 | Hans Garmo PhD3,4 | Klaus Brasso MD, PhD1,2 | Lars Egevad MD, PhD5 | Pär Stattin MD, PhD6,7

1Department of Urology, Copenhagen University Hospital – Rigshospitalet, Copenhagen Prostate Cancer Center, Copenhagen, Denmark
2Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
3Regional Cancer Centre Uppsala Örebro, Uppsala University Hospital, Uppsala, Sweden
4Division of Cancer Studies, King’s College London, School of Medicine, Cancer Epidemiology Group, London, UK
5Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden
6Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden
7Department of Surgical and Perioperative Sciences, Urology, and Andrology, Umeå University Hospital, Umeå, Sweden

Abstract
Background and Objective: Changes in diagnostic work-up, histopathological assessment, and treatment of men with prostate cancer during the last 20 years have affected the prognosis. The objective was to investigate the risk of prostate cancer death in men with clinically localised prostate cancer treated with radical prostatectomy in Sweden in 2000–2010.

Methods: Population-based, nationwide, study on men with clinically localised prostate cancer treated with radical prostatectomy in the period 2000–2010. Cox regression analyses were used to assess differences in risk of prostate cancer death according to calendar period for diagnosis and stratified on risk category.

Results: The study included 19,330 men with a median follow-up of 12.4 years. Men diagnosed in 2007–2008 and 2009–2010 had a significantly lower risk of prostate cancer death compared to men diagnosed in 2000–2002. The reduced risk of prostate cancer death was restricted to men with intermediate-risk prostate cancer with no differences observed in men with low- or high-risk prostate cancer.

Conclusion: During the study period, the risk of prostate cancer death decreased in the total population of men with localised prostate cancer treated with radical prostatectomy. The decrease was restricted to men with intermediate-risk prostate cancer.

KEYWORDS
mortality, PCBaSe, prostate cancer, radical prostatectomy
1. INTRODUCTION

To inform on treatment options knowledge of the natural history of the disease at hand as well as the effect of interventions are imperative. The natural history of localised prostate cancer is best known in men diagnosed in the 1970s and 1980s, while outcomes following curatively intended treatment have primarily been studied in randomised controlled trials in men diagnosed in the 1990s and 2000s. During the 1990s and 2000s an increased use of prostate specific-antigen (PSA) testing, increased number of diagnostic biopsies sampled, and revisions of histopathological grading criteria occurred. Taken together these changes have caused a stage and grade migration, which resulted in a seemingly better prognosis for men with prostate cancer diagnosed in more contemporary calendar periods.

The aim of the present study was to investigate temporal changes in the risk of prostate cancer death in men with localised prostate cancer treated with radical prostatectomy in Sweden in 2000–2010.

2. MATERIAL AND METHODS

Prostate Cancer data Base Sweden (PCBaSe) 4.0 contains information on cancer characteristics and primary treatment from the National Prostate Cancer Register (NPCR). Data on comorbidity (CCI) were obtained from the Patient Registry, data on educational level and marital status were obtained from The Longitudinal database on socioeconomic factors (LISA), and data on cause and date of death were obtained from the Cause of Death Registry.

This study included men with clinically localised prostate cancer aged 75 years or younger diagnosed in the period 2000–2010 who underwent radical prostatectomy within 6 months from diagnosis. Localised prostate cancer was defined as: T1-2, PSA < 50 ng/ml and without evidence of dissemination (NOxM0x). We used a modification of the NCCN risk categorisation to stratify on risk categories: Low-risk (T1-2 and PSA < 10 ng/ml and Gleason score ≤ 6); intermediate-risk (T1-2 and/or PSA 10–20 ng/ml and/or Gleason score 7 [3 + 4 or 4 + 3]), and high-risk (T1-2 and/or PSA > 20 ng/ml and/or Gleason score 8–10).

The following variables were available: age at diagnosis, T stage, Gleason score on biopsy, serum level of PSA (ng/ml), the proportion of positive biopsy cores, CCI, education level, marital status, and the annual number of radical prostatectomies performed at treating hospital the year before diagnosis.

Follow-up was calculated from the date of prostate cancer diagnosis to death, emigration, or end of the study period (December 31, 2019), whichever came first. Death was classified as prostate cancer death or non-prostate cancer death. The Research Ethics Board at Umeå University Hospital approved the study.

2.1. Statistical methods

Follow-up was calculated with the reverse Kaplan–Meier method. Cumulative incidences with 95% confidence intervals (CI) of prostate cancer death were estimated with competing risk analyses treating death from other causes as competing events and vice versa. Univariable Cox regression analyses were applied to investigate the association between risk of prostate cancer death by year of diagnosis (2000–2002, 2003–2004, 2005–2006, 2007–2008, and 2009–2010), age (<60, 60–65, 65–70, 70+), T stage (1, 2), Gleason score (≤6, 7 [3 + 4], 7 [4 + 3], 8, and 9–10), PSA (0–<10, 10–<20, and 20–<50), the proportion of positive biopsy cores (<16.7%, 16.7%–33%, 34%–50%, >50%, and missing), CCI (0, 1, and 2+), education level (low, middle, high, and missing), marital status (married and not married), and the annual number of radical prostatectomies performed at treating hospital the year before treatment (stratified in quartiles).

All tests were two-sided and the significance level was set to \( p < 0.05 \). Statistical analysis was performed with R version 4.0.0 (R Foundation for Statistical Computing).

3. RESULTS

The study includes 19,330 men diagnosed with localised prostate cancer in 2000–2010 who underwent primary radical prostatectomy within 6 months from diagnosis. The median follow-up was 12.4 years, ranging from 9.1 to 17.2 years. During the study period the proportion of men aged 65 years or above increased, as did the proportion of men with clinical stage T1 and men with Gleason scores ≤ 6, Table 1. The number of biopsy cores increased from a median of 6 (IQR 6–6) in 2000–2002 to 10 (IQR 8–10) in 2009–2010. Baseline characteristics stratified on risk category are available in Table S1. In men with low-risk prostate cancer there was an increase in the proportion of men with T1 tumours. In men with intermediate- and high-risk prostate cancer the median PSA decreased while there was an increase in proportion of men with T1 tumours. In men with high-risk prostate cancer, the proportion of men with Gleason scores 8–10 increased from 53% in 2000–2002 to 67% in 2009–2010 and the proportion of men with CCI 1 or higher increased from 8% in 2000–2002 to 17% in 2009–2010.

The 9-year overall mortality decreased from 9.4% (95% CI 8.4%–10.5%) in 2000–2002 to 7.3% (95% CI 6.5%–8%) in 2009–2010. The cumulative incidence of prostate cancer and nonprostate cancer death is depicted in Figure 1. Overall, cumulative prostate cancer deaths following 9 years remained unchanged with 1.7% (95% CI 1.2%–2.1%) of men diagnosed in 2000–2002 compared with 1.4% (95% CI 1.1%–1.8%) of men in 2009–2010. In the same period, the nonprostate cancer deaths declined from 7.8% (95% CI 6.8%–8.8%) to 5.9% (95% CI 5.2%–6.5%). In univariable Cox regression analyses lower risk of prostate cancer death was seen in men diagnosed in later calendar periods, men with higher education level and men diagnosed in hospitals performing the highest annual number of prostatectomies, Table 2; whereas the higher
| TABLE 1 | Baseline characteristics of 19 330 men in Prostate Cancer data Base Sweden (PCBaSe) diagnosed with localised prostate cancer and treated with radical prostatectomy stratified on calendar period of diagnosis |
|-------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|
|                              | 2000–2002 n = 2544                                | 2003–2004 n = 3353                                | 2005–2006 n = 3743                                | 2007–2008 n = 3605                                | 2009–2010 n = 2298                                |
| **Age at diagnosis, years**  |                                                  |                                                  |                                                  |                                                  |                                                  |
| ≤60                          | 984 (35)                                         | 1202 (32)                                        | 1268 (31)                                        | 1171 (30)                                        | 1316 (28)                                        |
| 60–<65                       | 886 (31)                                         | 1235 (33)                                        | 1441 (35)                                        | 1325 (34)                                        | 1480 (31)                                        |
| 65–<70                       | 766 (27)                                         | 973 (26)                                         | 1050 (26)                                        | 1120 (28)                                        | 1462 (31)                                        |
| 70+                          | 191 (7)                                          | 297 (8)                                          | 350 (9)                                          | 315 (8)                                          | 498 (10)                                         |
| **Clinical tumour category** |                                                  |                                                  |                                                  |                                                  |                                                  |
| T1                           | 1650 (58)                                        | 2366 (64)                                        | 2763 (67)                                        | 2570 (65)                                        | 3223 (68)                                        |
| T2                           | 1177 (42)                                        | 1341 (36)                                        | 1346 (33)                                        | 1361 (35)                                        | 1533 (32)                                        |
| **Gleason score**            |                                                  |                                                  |                                                  |                                                  |                                                  |
| ≤6                           | 1986 (76)                                        | 2589 (71)                                        | 2701 (67)                                        | 2224 (57)                                        | 2354 (50)                                        |
| 7 (3 + 4)                    | 359 (14)                                         | 683 (19)                                         | 805 (20)                                         | 1055 (27)                                        | 1465 (31)                                        |
| 7 (4 + 3)                    | 136 (5)                                          | 221 (6)                                          | 326 (8)                                          | 380 (10)                                         | 572 (12)                                         |
| 8                            | 97 (4)                                           | 137 (4)                                          | 167 (4)                                          | 203 (5)                                          | 276 (6)                                          |
| 9–10                         | 29 (1)                                           | 31 (1)                                           | 39 (1)                                           | 51 (1)                                           | 78 (2)                                           |
| **PSA at diagnosis, ng/ml**  |                                                  |                                                  |                                                  |                                                  |                                                  |
| Median (IQR)                 | 8 (5–11)                                         | 7 (5–11)                                         | 7 (5–10)                                         | 7 (5–10)                                         | 6 (5–10)                                         |
| **Proportion positive biopsy cores, %** |                                                  |                                                  |                                                  |                                                  |                                                  |
| Median (IQR)                 | 33 (17–50)                                       | 33 (17–50)                                       | 33 (17–50)                                       | 33 (20–50)                                       | 30 (20–50)                                       |
| Missing                      | 1 749 (69%)                                      | 304 (9%)                                         | 406 (11%)                                        | 113 (3%)                                         | 74 (3%)                                          |
| **Charlson comorbidity index** |                                                  |                                                  |                                                  |                                                  |                                                  |
| 0                            | 2588 (92)                                        | 3319 (90)                                        | 3621 (88)                                        | 3443 (88)                                        | 4106 (86)                                        |
| 1                            | 166 (6)                                          | 285 (8)                                          | 350 (9)                                          | 359 (9)                                          | 470 (10)                                         |
| 2+                           | 73 (3)                                           | 103 (3)                                          | 138 (3)                                          | 129 (3)                                          | 180 (4)                                          |
| **Education level**          |                                                  |                                                  |                                                  |                                                  |                                                  |
| Low                          | 896 (32)                                         | 1102 (30)                                        | 1145 (28)                                        | 1054 (27)                                        | 1226 (26)                                        |
| Middle                       | 1143 (40)                                        | 1524 (41)                                        | 1698 (41)                                        | 1615 (41)                                        | 1949 (41)                                        |
| High                         | 776 (27)                                         | 1066 (29)                                        | 1251 (30)                                        | 1244 (32)                                        | 1564 (33)                                        |
| Missing                      | 12 (0)                                           | 15 (0)                                           | 15 (0)                                           | 18 (0)                                           | 17 (0)                                           |
| **Marital status**           |                                                  |                                                  |                                                  |                                                  |                                                  |
| Married                      | 2179 (77)                                        | 2779 (75)                                        | 3066 (75)                                        | 2877 (73)                                        | 3367 (71)                                        |
| Not married                  | 648 (23)                                         | 928 (25)                                         | 1043 (25)                                        | 1054 (27)                                        | 1389 (29)                                        |
| **Annual procedures performed at treating hospital** |                                                  |                                                  |                                                  |                                                  |                                                  |
| Median (IQR)                 | 38 (19–74)                                       | 53 (29–121)                                      | 62 (40–126)                                      | 60 (37–131)                                      | 69 (40–159)                                      |

Abbreviations: IQR, interquartile range; PSA, prostate specific-antigen.
risk of prostate cancer death was seen in older men, men with T2, higher Gleason score, higher PSA, more cancer in biopsies and CCI 2 or higher. In multivariate Cox regression analyses, men diagnosed in 2007–2008 (hazard ratio [HR] 0.70 [95% CI 0.49–0.97]) and 2009–2010 (HR 0.58 [95% CI 0.41–0.84]) had a lower risk of prostate cancer death compared with men diagnosed in 2000–2002; whereas age, T stage, Gleason score, PSA, cancer in biopsies, and comorbidity still were associated with a higher risk of prostate cancer death. 

Stratified on risk category the cumulative prostate cancer mortality was 0.6% (95% CI 0.2%–1.0%) in 2000–2002 and 0.4% (95% CI 0.1%–0.7%) in 2009–2010 for men with low-risk prostate cancer, Figure 2. Corresponding numbers for men with intermediate-risk and high-risk prostate cancer were 2.8% (95% CI 1.8%–3.8%) and 1.2% (95% CI 0.8%–1.7%), and 3.4% (1.2–5.6) and 6.0% (95% CI 4.0%–8.1%), respectively. In men with intermediate-risk prostate cancer the cumulative prostate cancer deaths decreased significantly by calendar period for diagnosis, whereas cumulative prostate cancer death showed no systematic change over time in men with low- or high-risk prostate cancer, Table 3. In addition, the ratio of prostate cancer deaths/nonprostate cancer deaths decreased in men with intermediate-risk prostate cancer from 0.24 in 2000–2002 to 0.15 in 2009–2010.

In multivariable Cox regression analyses men with intermediate-risk prostate cancer diagnosed in 2007–2008 (HR 0.56 [95% CI 0.33–0.95]) and 2009–2010 (HR 0.47 [95% CI 0.27–0.82]) had a significantly lower risk of prostate cancer death compared with men diagnosed in 2000–2002, Table 4. There was no significant difference in risk of prostate cancer death between diagnostic periods for men classified with low- or high-risk prostate cancer. Full multivariable Cox regression analyses stratified on risk category are available in Table S2.

4. DISCUSSION

In this nationwide, population-based study of Swedish men diagnosed with localised prostate cancer in 2000–2010 treated with radical prostatectomy, we found lower all-cause mortality in men diagnosed in more recent calendar periods, which was caused by a decrease in nonprostate cancer deaths. This is likely the result of an increased life expectancy in the general Swedish population. Only in men with intermediate-risk prostate cancer was there a decrease in risk of prostate cancer death, whereas no significant changes were found in men with low- or high-risk prostate cancer.

Limitations of this study include the use of data from the original histopathological reports of diagnostic prostate biopsies without centralised review and that we were unable to assess the impact on the outcome of each change that occurred during the study period. Strengths of our study include a large nationwide, population-based cohort of men with comprehensive data from several high-quality healthcare registers. We chose to only include men treated with radical prostatectomy to try and reduce biases caused by changes in treatment strategies. Besides changes in surgical technique, changes in case-mix, work-up, and histopathological assessment of biopsies likely also affected outcome. During the study period, an increasing proportion of men with very low-risk prostate cancer were managed by active surveillance and more men with high-risk prostate cancer and high comorbidity underwent radical prostatectomy (Table S1). This could be the reason why we did not detect any changes in the risk of prostate cancer death in these risk categories.

A number of changes occurred during the study period, which may have contributed to the fewer number of deaths in men diagnosed with intermediate-risk prostate cancer in the most recent calendar periods. Because of the increased use of PSA testing in asymptomatic men, the incidence of prostate cancer has dramatically increased during the last decades in most Western countries. PSA testing in asymptomatic men effectively changes the stage at diagnosis by significantly reducing the number of men diagnosed with advanced prostate cancer and consequently increases the number of men diagnosed with localised prostate cancer. Additionally, the median number of biopsy cores taken at diagnostic work-up increased from 6 to 10, which results in an estimated increase in the number of prostate cancers detected by 31%, including small, clinically insignificant cancers. Finally, the Gleason grading...


**TABLE 2** Uni- and multivariable Cox regression analyses for risk of prostate cancer death

| Diagnosis period | Univariable | Multivariable |
|------------------|-------------|---------------|
|                  | HR 95% CI   | HR 95% CI     |
| 2000–2002        | Ref         | Ref           |
| 2003–2004        | 0.84 (0.66–1.07) | 1.06 (0.80–1.42) |
| 2005–2006        | 0.65 (0.50–0.85) | 0.80 (0.59–1.09) |
| 2007–2008        | 0.66 (0.49–0.87) | 0.70 (0.49–0.97) |
| 2009–2010        | 0.59 (0.43–0.80) | 0.58 (0.41–0.84) |

| Age, year       | Univariable | Multivariable |
|-----------------|-------------|---------------|
| <60             | Ref         | Ref           |
| 60–<65          | 1.29 (1.02–1.64) | 1.16 (0.91–1.49) |
| 65–<70          | 1.90 (1.51–2.40) | 1.54 (1.21–1.97) |
| 70+             | 2.85 (2.14–3.79) | 1.77 (1.31–2.39) |

| Clinical tumour category | Univariable | Multivariable |
|--------------------------|-------------|---------------|
| T1                       | Ref         | Ref           |
| T2                       | 2.64 (2.22–3.13) | 1.65 (1.37–1.98) |

| Gleason score           | Univariable | Multivariable |
|-------------------------|-------------|---------------|
| ≤6                      | Ref         | Ref           |
| 7 (3 + 4)               | 2.93 (2.33–3.69) | 2.43 (1.92–3.09) |
| 7 (4 + 3)               | 5.28 (4.06–6.86) | 4.11 (3.14–5.38) |
| 8                       | 7.67 (5.79–10.16) | 6.16 (4.61–8.23) |
| 9–10                    | 25.03 (18.27–34.25) | 16.76 (12.06–23.30) |

| PSA, ng/ml              | Univariable | Multivariable |
|-------------------------|-------------|---------------|
| 0–10                    | Ref         | Ref           |
| 10–20                   | 2.09 (1.74–2.51) | 1.39 (1.14–1.70) |
| 20–50                   | 3.48 (2.64–4.57) | 2.09 (1.57–2.78) |

| Proportion positive biopsy core | Univariable | Multivariable |
|---------------------------------|-------------|---------------|
| <16.7%                          | Ref         | Ref           |
| 16.7%–33%                      | 1.24 (0.81–1.90) | 1.35 (0.87–2.11) |
| 34%–50%                        | 2.61 (1.88–3.62) | 2.20 (1.56–3.10) |
| >50%                            | 5.06 (3.62–7.04) | 3.53 (2.48–5.02) |
| Missing                         | 3.15 (2.23–4.45) | 2.39 (1.61–3.55) |

| Charlson comorbidity index     | Univariable | Multivariable |
|--------------------------------|-------------|---------------|
| 0                               | Ref         | Ref           |
| 1                               | 1.16 (0.86–1.56) | 1.01 (0.73–1.38) |
| 2+                              | 1.93 (1.29–2.88) | 1.90 (1.25–2.87) |

| Education                     | Univariable | Multivariable |
|--------------------------------|-------------|---------------|
| Low                            | Ref         | Ref           |
| Middle                         | 0.81 (0.67–0.99) | 0.92 (0.75–1.14) |
| High                           | 0.79 (0.64–0.99) | 0.94 (0.75–1.18) |
| Missing                        | 1.41 (0.45–4.42) | 0.81 (0.20–3.25) |

(Continues)

*Abbreviations: CI, confidence interval; HR, hazard ratio; PSA prostate specific-antigen.*

guidelines have changed, which has caused a grade migration upwards. Originally the Gleason score of needle biopsies was calculated as “the sum of the two predominant grades,” which in the modified 2005 guidelines were changed to “the sum of the most predominant grade and the highest grade present.” In cases where the predominant grades included the highest grade present, lower grades should only be included in the Gleason score if they constituted more than 5% of the tumour volume. Moreover, regular cribriform glands, which were previously classified as Gleason pattern 3 were now considered Gleason pattern 4. In Sweden among men diagnosed with stage T1 prostate cancer and PSA <10 ng/ml the proportion of men with Gleason scores 7–10 in the diagnostic biopsy specimen increased from 18% in 1998 to 40% in 2011. Other studies have shown that 34%–55% men with original Gleason score 6 were reclassified with higher Gleason scores when assessed according to the modified 2005 guidelines. Thus, without change in the overall prognosis, the prognosis of both Gleason score 6 and Gleason score 7 (3 + 4) improved, as the most aggressive prostate cancers that used to be assigned a Gleason score 6 would be reclassified as Gleason score 7 (3 + 4), that is, an example of Will Rogers phenomenon. Thus, the fewer observed prostate cancer deaths in men with intermediate-risk prostate cancer seem logical because the influence of the stage and grade migration influenced outcome for this risk group the most.

Risk stratification of men with localised prostate cancer is based on T stage, Gleason score, and PSA. The original D’Amico risk classification stratified men into three risk groups: low-, intermediate-, and high-risk. In recent years “very low-risk prostate cancer” has been included as a fourth risk group accounting also for the prostate volume. The original D’Amico definition of intermediate-risk prostate cancer was based on three intermediate-risk criteria: T2b, PSA 10–20 ng/ml, and Gleason score 7. Thus, men can have from 1 to 3 intermediate-risk criteria. The risk of biochemical recurrence following radical prostatectomy is higher in men with 2–3 intermediate-risk
FIGURE 2 Cumulative probability of prostate cancer (PCa) deaths for men with localised PCa treated with radical prostatectomy in 2000–2010 stratified on diagnostic period and risk group [Color figure can be viewed at wileyonlinelibrary.com]
criteria compared with men with only 1 intermediate-risk criterion. This suggests that men with intermediate-risk prostate cancer could likely be stratified in a “favourable” and an “unfavourable” risk group.

The lower prostate cancer mortality indicates that active surveillance could be an alternative strategy for some men with intermediate-risk prostate cancer. To date no randomised study has compared radical prostatectomy to an active surveillance strategy. But a recent matched-pair analysis of two nationwide Danish cohorts found no difference in prostate cancer mortality after 10 years between 276 men with intermediate-risk prostate cancer treated with radical prostatectomy and 271 men with intermediate-risk prostate cancer managed on active surveillance.

| TABLE 3 | Number of prostate cancer and nonprostate cancer deaths with 9 years follow-up and 9 year cumulative incidence estimates |
|---------|-------------------------------------------------------------|
| Prostate cancer death | Nonprostate cancer death |
| No of events/no at risk | Cumulative incidence% (95% CI) | No of events/no at risk | Cumulative incidence% (95% CI) |
| Low-risk |
| 2000–2002 | 9/1 503 | 0.6 (0.2–1) | 108/1 503 | 7.2 (5.9–8.5) | 9/117 | 0.08 |
| 2003–2004 | 7/1 923 | 0.4 (0.1–0.6) | 109/1 923 | 5.7 (4.7–6.7) | 7/116 | 0.06 |
| 2005–2006 | 16/2 140 | 0.8 (0.4–1.1) | 128/2 140 | 6.0 (5.0–7.0) | 16/144 | 0.11 |
| 2007–2008 | 9/1 719 | 0.5 (0.2–0.9) | 88/1 719 | 5.2 (4.1–6.2) | 9/97 | 0.09 |
| 2009–2010 | 7/1 854 | 0.4 (0.1–0.7) | 103/1 854 | 5.6 (4.6–6.7) | 7/110 | 0.06 |
| Intermediate-risk |
| 2000–2002 | 29/1 054 | 2.8 (1.8–3.8) | 92/1 054 | 8.8 (7.1–10.5) | 29/121 | 0.24 |
| 2003–2004 | 40/1 453 | 2.8 (1.9–3.6) | 118/1 453 | 8.1 (6.7–9.6) | 40/158 | 0.25 |
| 2005–2006 | 34/1 607 | 2.1 (1.4–2.8) | 110/1 607 | 6.9 (5.6–8.1) | 34/144 | 0.24 |
| 2007–2008 | 26/1 772 | 1.5 (0.9–2.0) | 112/1 772 | 6.3 (5.2–7.5) | 26/138 | 0.19 |
| 2009–2010 | 28/2 360 | 1.2 (0.8–1.7) | 158/2 360 | 5.6 (4.7–6.5) | 28/186 | 0.15 |
| High-risk |
| 2000–2002 | 9/266 | 3.4 (1.2–5.6) | 19/266 | 7.2 (4.1–10.3) | 9/28 | 0.32 |
| 2003–2004 | 34/324 | 10.5 (7.2–13.9) | 21/324 | 6.5 (3.8–9.2) | 34/55 | 0.62 |
| 2005–2006 | 19/353 | 5.4 (3.0–7.8) | 32/353 | 9.1 (6.1–12.1) | 19/51 | 0.37 |
| 2007–2008 | 34/426 | 8.0 (5.4–10.6) | 28/426 | 6.6 (4.2–8.9) | 34/62 | 0.55 |
| 2009–2010 | 32/533 | 6.0 (4.0–8.1) | 40/533 | 7.6 (5.3–9.9) | 32/72 | 0.44 |

Abbreviation: CI, confidence interval.

| TABLE 4 | Multivariate Cox regression analyses for risk of death from prostate cancer stratified on risk category |
|---------|-------------------------------------------------------------|
| | Low-risk | Intermediate-risk | High-risk |
| | HR | 95% CI | HR | 95% CI | HR | 95% CI |
| Diagnostic period |
| 2000–2002 | Ref | Ref | Ref |
| 2003–2004 | 0.61 (0.32–1.16) | 1.10 (0.72–1.69) | 1.36 (0.83–2.24) |
| 2005–2006 | 0.64 (0.33–1.27) | 0.86 (0.55–1.35) | 0.79 (0.45–1.39) |
| 2007–2008 | 0.63 (0.28–1.42) | 0.56 (0.33–0.95) | 0.98 (0.56–1.69) |
| 2009–2010 | 0.52 (0.20–1.34) | 0.47 (0.27–0.82) | 0.80 (0.45–1.42) |

Note: Adjusted for age at diagnosis, clinical tumour category, Gleason score, prostate-specific antigen, percent positive biopsy cores, CCI, education, marital status, and a number of procedures performed at treating hospital.

Abbreviations: CI, confidence interval; HR, hazard ratio.
surveillance in 2002-2012. The majority of men in this study had one intermediate-risk criterion and either Gleason score 6 or 7 (3 + 4). We still need additional studies to investigate this strategies safety in these men.

In the 2010s MRI has been introduced in the diagnostic work-up of prostate cancer and additional changes have been made to the histopathological assessment. Both these changes could potentially again change the prostate cancer prognosis—especially in men with localised prostate cancer. It is unknown—but seems unlikely—that a prostate cancer found following an MRI targeted biopsy of a suspicious lesion has the same oncological risk as a similar prostate cancer found following systematic TRUS guided biopsies. It is essential that we continue to study the changes that new guidelines and modalities entails to understand how this affects our understanding of prostate cancer.

5. CONCLUSION

During the 11-year study period, there was a gradual decrease in risk of death from nonprostate cancer causes in men with localised prostate cancer treated with radical prostatectomy in Sweden. A decrease in prostate cancer deaths was restricted to men with intermediate-risk prostate cancer, likely explained by changes in disease characteristics most strongly affecting this risk category.

ACKNOWLEDGMENTS

This project was made possible by the continuous work of the National Prostate Cancer Register of Sweden (NPCR) steering group: Pär Stattin (chairman), Ingela Franck Lissbrant (co-chair), Camilla Thellenberg, Johan Styrke, Eva Johansson, Hampus Nugin, Magnus Törnblom, Stefan Carlsson, David Robinson, Mats Andén, Johan Stranne, Jonas Hugosson, Maria Nyberg, Per Fransson, Fredrik Sandin and Karin Hellström, Gert Malmberg, Hans Joellson. This study was supported by The Swedish Cancer Society (190030), and Region Uppsala. These grants were unconditional and the funding organisation had no influence on the work performed.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

All authors contributed to the manuscript and approved of the final version. Frederik B. Thomsen had full access to the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. There were no other contributors to the manuscript except those on the author list.

DATA AVAILABILITY STATEMENT

The Research Ethics Board at Uppsala University approved of the linkages in our project (PCBaSe 2016-239). We received a study file from Statistics Sweden and the National Board of Health and Welfare where the person identity number for men in the National prostate Cancer Register had been replaced by a code. This means that the data set is pseudonymized, but due to a large number of variables this data set is still considered not anonymized when deleting this code. The following restrictions apply: we are not allowed to share data on individuals with other researchers, nor or we allowed to upload such data on an open server. However, we can provide access to the data set on a remote server on demand. On the Research platform, data can be uploaded and then accessed by external researchers. However, no individual data are allowed to leave the platform but aggregated data in the form of figures and Tables can be exported.

This study was approved by the Research Ethics Board at Uppsala University and included all men in NPCR who were diagnosed with localised prostate cancer in 2000-2010 and who underwent radical prostatectomy within 6 months from diagnosis. External researcher should contact the corresponding author who will direct the demand for data to the PCBaSe reference group who will then provider the access described above.

REFERENCES

1. Popiolek M, Rider JR, Andrén O, et al. Natural history of early, localized prostate cancer: a final report from three decades of follow-up. Eur Urol. 2013;63:428-435.
2. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095-2101.
3. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in prostate cancer: 29-year follow-up. N Engl J Med. 2018;379:2319-2329.
4. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2017;375:1415-1424.
5. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203-213.
6. Wilt TJ, Vo TN, Langsetmo L. Radical prostatectomy or observation for clinically localized prostate cancer: extended follow-up of the prostate cancer intervention versus observation trial (PIVOT). Eur Urol. 2020;77:713-724.
7. Melia J, Mass S, Johns L. Contributors in the participating laboratories. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94:51-56.
8. Hjertholm P, Fenger-Grøn M, Vestergaard M, et al. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study. Int J Cancer. 2015;136:435-442.
9. Eichler K, Hempel S, Wilby J, Myers L, Bachmann LM, Kleijnen J. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol. 2006;175:175-182.
10. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
11. Danneman D, Drevin L, Robinson D, Stattin P, Egevad L. Gleason inflation 1998-2011: a registry study of 97,168 men. BJU Int. 2015;115:248-255.
12. Rader MA, Brasso K, Christensen IJ, et al. Changes in preoperative characteristics in patients undergoing radical prostatectomy: a 16-year nationwide analysis. Acta Oncol. 2014;53:361-367.
13. Moore AL, Dimitropoulou P, Lane A, et al. Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU Int. 2009;104:1592-1598.
14. Okihara K, Nakanishi H, Nakamura T, Mizutani Y, Kawauchi A, Miki T. Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol. 2005;12:662-667.

15. Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. BJU Int. 2019;123:421-428.

16. Helgstrand JT, Røder MA, Klemann N, et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer. 2018;124:2931-2938.

17. Van Hemelrijck M, Garmo H, Wigertz A, Nilsson P, Stattin P. Cohort Profile Update: The National Prostate Cancer Register of Sweden and Prostate Cancer data Base-a refined prostate cancer trajectory. Int J Epidemiol. 2015;45:73-82.

18. Van Hemelrijck M, Wigertz A, Sandin F, et al. Cohort Profile: the National Prostate Cancer Register of Sweden and Prostate Cancer data Base Sweden 2.0. Int J Epidemiol. 2013;42:956-967.

19. Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54:158-163.

20. Tomic K, Sandin F, Wigertz A, Robinson D, Lambe M, Stattin P. Evaluation of data quality in the National Prostate Cancer Register of Sweden. Eur J Cancer. 2015;51:101-111.

21. Berglund A, Garmo H, Tishelman C, Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011;185:833-839.

22. Ludvigsson JF, Svedberg P, Olén O, Bruze G, Neovius M. The longitudinal integrated database for health insurance and labour market studies (LISA) and its use in medical research. Eur J Epidemiol. 2019;34:423-437.

23. Godtman R, Holmberg E, Stranne J, Hugosson J. High accuracy of Swedish death certificates in men participating in screening for prostate cancer: a comparative study of official death certificates with a cause of death committee using a standardized algorithm. Scand J Urol Nephrol. 2011;45:226-232.

24. Meyer AC, Drefahl S, Ahlbom A, Lambe M, Modig K. Trends in life expectancy: did the gap between the healthy and the ill widen or close? BMC Med. 2020;18:41.

25. Loeb S, Folkvord Y, Curnyn C, Robinson D, Bratt O, Stattin P. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 2017;3:1393-1398.

26. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7-30.

27. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-1092.

28. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;6736:1-9.

29. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-732.

30. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125-128.

31. Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch. 2006;449:622-627.

32. Delahunt B, Lamb DS, Sigley JR, et al. Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point. Pathology. 2010;42:339-343.

33. Dong F, Wang C, Farris AB, et al. Impact on the clinical outcome of prostate cancer by the 2005 international society of urological pathology modified Gleason grading system. Am J Surg Pathol. 2012;36:838-843.

34. D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.

35. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-SI e guidelines on prostate cancer-2020 Update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243-262.

36. Kurbegovic S, Berg KD, Thomsen FB, et al. The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. Scand J Urol 2017;51(6):450-456.

37. Thomsen FB, Røder MA, Jakobsen H, et al. Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. Clin Genitourin Cancer. 2019;17:e814-e821.

38. Epstein J, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2020;44(244-252)

39. Vickers A, Carlsson SV, Cooperberg M. Routine use of magnetic resonance imaging for early detection of prostate cancer is not justified by the clinical trial evidence. Eur Urol. 2020;78:3-5.

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Thomsen FB, Garmo H, Brasso K, Egevad L, Stattin P. Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. J Surg Oncol. 2021;1-9. https://doi.org/10.1002/jso.26579